Charles S. Fuchs - 24 Jul 2026 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Reporting relationship: Director
Issuer ticker: CTMX
Reported as of: 24 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Jul 2026, 17:07:20 UTC
Next SEC filing: 12 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Christopher Ogden, as Attorney-in-Fact for Charles S. Fuchs

Key filing fact

Charles S. Fuchs filed Form 4 for CytomX Therapeutics, Inc. (CTMX) on 30 Jul 2026.

Key facts

This page summarizes Charles S. Fuchs's Form 4 filing for CytomX Therapeutics, Inc. (CTMX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 Jul 2026, 17:07.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001719576 Primary reporting owner

Fuchs Charles S.

Relationship: Director
Address: C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO
Signature: /s/ Christopher Ogden, as Attorney-in-Fact for Charles S. Fuchs
Signature date: 30 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTMX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +118,000
Change %
Price: $0.000000^*
Shares after: 118,000
Date: 24 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 118,000
Exercise price: $3.24
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/36th of the shares subject to the option vest on each monthly anniversary measured from July 24, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.